Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 34006597.
- Also identified by DOI 10.1126/science.abg8985 and PMC identifier 8168615.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The identification of CD4<sup>+</sup> T cell epitopes is instrumental for the design of subunit vaccines for broad protection against coronaviruses. Here, we demonstrate in COVID-19-recovered individuals a robust CD4<sup>+</sup> T cell response to naturally processed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein and nucleoprotein (N), including effector, helper, and memory T cells. By characterizing 2943 S-reactive T cell clones from 34 individuals, we found that the receptor-binding domain (RBD) is highly immunogenic and that 33% of RBD-reactive clones and 94% of individuals recognized a conserved immunodominant S346-S365 region comprising nested human leukocyte antigen DR (HLA-DR)- and HLA-DP-restricted epitopes. Using pre- and post-COVID-19 samples and S proteins from endemic coronaviruses, we identified cross-reactive T cells targeting multiple S protein sites. The immunodominant and cross-reactive epitopes identified can inform vaccination strategies to counteract emerging SARS-CoV-2 variants.
Medical subject headings
- CD4-Positive T-Lymphocytes
- COVID-19
- Immunodominant Epitopes
- SARS-CoV-2
- Spike Glycoprotein, Coronavirus